This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Top Stock Reports for Home Depot, Southern Company & Infosys
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), The Southern Company (SO) and Infosys Ltd. (INFY), as well as two micro-cap stocks Kewaunee Scientific Corp. (KEQU) and Friedman Industries, Inc. (FRD).
Why McKesson (MCK) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
McKesson (MCK) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
McKesson (MCK) reachead $518.81 at the closing of the latest trading day, reflecting a +1.49% change compared to its last close.
McKesson (MCK) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
McKesson (MCK) concluded the recent trading session at $511.17, signifying a +0.14% move from its prior day's close.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson Shares Fall Following Sale of Rexall, Well.ca to Birch Hill
by Zacks Equity Research
MCK announces the sale of its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, aligning with its strategy to grow oncology and biopharma services.
Stock Market News for Sep 6, 2024
by Zacks Equity Research
Markets finished mixed on Thursday as soft economic data raised concerns of a recession and doubts about whether the Fed is behind the curve on interest rate cuts.
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson (MCK) Upgraded to Buy: Here's Why
by Zacks Equity Research
McKesson (MCK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
by Zacks Equity Research
Here is how Atea Pharmaceuticals, Inc. (AVIR) and McKesson (MCK) have performed compared to their sector so far this year.
Should Value Investors Buy McKesson (MCK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wall Street Analysts See McKesson (MCK) as a Buy: Should You Invest?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in McKesson (MCK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VALQ
MCK Stock's Uptrend Likely to Continue After Core Ventures Acquisition
by Zacks Equity Research
McKesson's agreement to acquire a controlling interest will likely bring advanced treatments and improved care experiences to patients.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
McKesson (MCK) Stock Gains 18% YTD: What's Driving the Rally?
by Harshit Gupta
McKesson's (MCK) shares rally on the back of solid fundamentals. Increasing volumes of prescription and specialty drugs boost the top line.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
McKesson (MCK) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
McKesson's (MCK) first-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
McKesson (MCK) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for McKesson (MCK) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
McKesson (MCK) Tops Q1 Earnings Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 10.06% and 4.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why McKesson (MCK) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Henry Schein (HSIC) Q2 Earnings Beat Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 0.82% and 4.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy, Sell or Hold McKesson (MCK) Before Q1 Earnings?
by Zacks Equity Research
McKesson's (MCK) first-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
Unlocking Q1 Potential of McKesson (MCK): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for McKesson (MCK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
McKesson (MCK) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
McKesson (MCK) reachead $629.09 at the closing of the latest trading day, reflecting a +1.96% change compared to its last close.